The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...

Many novel drugs are more relevant for subspecialists, but of the six first-in-class medications approved by the US Food and ...

European shares fell on Tuesday as heavyweight Novo Nordisk slumped, while U.S. President Donald Trump's vocal attacks on ...

Suspicious Ozempic products should be reported to Novo Nordisk or directly to the FDA. In addition, any adverse effects from ...

Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of ...

Novo Nordisk's (NVO) stock price dropped following Eli Lilly's announcement of positive Phase 3 trial results for its oral ...

Novo Nordisk A/S slumped after a pill from rival Eli Lilly & Co. helped patients shed weight and control blood sugar about as ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk (NYSE:NVO) shares sank more than 7% in Copenhagen after Eli Lilly (NYSE:LLY) released promising trial results for its experimental obesity pill, orforglipron, which showed weight loss and ...

Novo Nordisk (NYSE:NVO) stock has experienced a significant decline, dropping 35% from over $90 in early March to around $58 ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

The global capability centre of Novo Nordisk in India is now closely engaged with the entire value chain of this global ...